Stockreport

Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity

Inhibikase Therapeutics, Inc.  (IKT) 
PDF BOSTON and ATLANTA, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company [Read more]